Department of Cardiothoracic Surgery, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China; ; Guangzhou Institute of Respiratory Disease & China State Key Laboratory of Respiratory Disease, Guangzhou 510120, China.
J Thorac Dis. 2013 Aug;5 Suppl 3(Suppl 3):S267-73. doi: 10.3978/j.issn.2072-1439.2013.08.24.
To explore the feasibility of complete video-assisted thoracoscopic surgery (c-VATS) following neoadjuvant therapy (chemotherapy, targeted therapy and radiotherapy, either alone or in combination) for the treatment of patients with non-small cell lung cancer (NSCLC).
The clinical data of 43 NSCLC patients undergoing c-VATS following neoadjuvant therapy were retrospectively analyzed, including the preoperative functional indicators, staging, concurrent diseases, surgical techniques, operation time, number of lymph nodes dissected and postoperative drainage time and quantity, postoperative hospital stay, postoperative complications, and survival.
From January 2006 to March 2012, a total of 43 patients with stage IIA-IIIB NSCLC were included in this study (IIIA: 27 cases, 62.8%; IIIB: 11 cases, 25.6%), including 32 males (74.4%) and 11 females (25.6%). Forty-two patients were operated successfully, 28 underwent pulmonary lobectomies (including 9 bronchial sleeve resections), 5 had double lobectomies, 5 had wedge resections, and 4 had total pneumonectomies. Seven patients were referred to undergo Hybrid VATS (7/42, 16.7%). The mean length of the operation was 160.48±16.52 min (range, 130-180 min); the intraoperative blood loss was 253.57±117.08 mL; the number of lymph nodes dissected was 16.88±10.93; the postoperative drainage time was 1-7 d (mean: 2.62±0.96 d); and the postoperative hospital stay was 3-7 d (mean: 5.45±1.30 d). The incidence of postoperative complications was 9.5% (4/42), and the perioperative mortality was 2.4% (1/42). The 1-, 2-, and 3-year overall survival rates were 94%, 79%, and 65%, respectively.
c-VATS following neoadjuvant therapy is safe and feasible for the treatment of locally advanced NSCLC.
探讨新辅助治疗(化疗、靶向治疗和放疗,单独或联合应用)后完全电视辅助胸腔镜手术(c-VATS)治疗非小细胞肺癌(NSCLC)的可行性。
回顾性分析 43 例新辅助治疗后行 c-VATS 的 NSCLC 患者的临床资料,包括术前功能指标、分期、合并症、手术技术、手术时间、清扫淋巴结数目及术后引流时间和引流量、术后住院时间、术后并发症及生存情况。
2006 年 1 月至 2012 年 3 月,共纳入 43 例ⅡA-ⅢB 期 NSCLC 患者(ⅢA 期:27 例,62.8%;ⅢB 期:11 例,25.6%),其中男 32 例(74.4%),女 11 例(25.6%)。42 例手术成功,28 例行肺叶切除术(包括 9 例支气管袖状切除术),5 例双肺叶切除术,5 例楔形切除术,4 例全肺切除术。7 例改行 Hybrid VATS(7/42,16.7%)。手术时间为 130-180min,平均 160.48±16.52min;术中出血量为 117.08±253.57mL;清扫淋巴结 10.93±16.88 枚;术后引流时间 1-7d,平均 2.62±0.96d;术后住院时间 3-7d,平均 5.45±1.30d。术后并发症发生率为 9.5%(4/42),围手术期死亡率为 2.4%(1/42)。1、2、3 年总生存率分别为 94%、79%、65%。
新辅助治疗后行 c-VATS 治疗局部晚期 NSCLC 是安全可行的。